Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics, Inc.'s Q·Score is 7/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $34.75 is 49% above current price. Key area to monitor: currently unprofitable (-4% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for ARQT is $34.75, based on ratings from 8 Wall Street analysts. This is 48.8% above the current price of $23.35. Price targets are forward-looking estimates and not guarantees of future performance.

Arcutis Biotherapeutics, Inc. (ARQT) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 19.4×. The consensus analyst price target of $34.75 is 49% above the current price.

Arcutis Biotherapeutics, Inc. is scheduled to report earnings in 3 days, on May 6, 2026.

Arcutis Biotherapeutics, Inc. has a net profit margin of -4.3%, indicating the company is currently operating at a net loss. Its gross margin stands at 90.2%, indicating a high-margin business model.

Arcutis Biotherapeutics, Inc. is reporting strong year-over-year growth of 81.5%.

Arcutis Biotherapeutics, Inc. has a debt-to-equity ratio of 0.60×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 3.17×, indicating comfortable short-term liquidity.